A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT02528643
- Locations
- 🇨🇦
Site CA15003, Montreal, Canada
🇨🇦Site CA15002, Montreal, Quebec, Canada
🇭🇰Site HK85204, Shatin, Hong Kong
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02495233
- Locations
- 🇯🇵
Site JP81005, Osakasayama, Osaka, Japan
🇯🇵Site JP81004, Fukuoka Minami-ku, Fukuoka, Japan
🇯🇵Site JP81003, Suntogun Nagaizumicho,Shizuoka, Japan
Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02456883
- Locations
- 🇺🇸
Site US10001, Cleveland, Ohio, United States
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02441517
- Locations
- 🇺🇸
Site US10004, New York, New York, United States
🇺🇸Site US10003, Evanston, Illinois, United States
🇺🇸Site US10002, Myrtle Beach, South Carolina, United States
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 371
- Registration Number
- NCT02421939
- Locations
- 🇵🇱
Site PL48004, Wroclaw, Poland
🇺🇸Site US10044, Cleveland, Ohio, United States
🇺🇸Site US10034, Boston, Massachusetts, United States
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT02383368
- Locations
- 🇺🇸
Site US10001, New Haven, Connecticut, United States
🇺🇸Site US10004, Chicago, Illinois, United States
🇺🇸Site US10002, Rochester, Minnesota, United States
Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1030
- Registration Number
- NCT02380274
- Locations
- 🇺🇸
Site US1123, Billings, Montana, United States
🇺🇸Site USSUB1048, Missoula, Montana, United States
🇺🇸Site USSUB1062, Billings, Montana, United States
Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT02372578
- Locations
- 🇺🇸
Site US10013, Kettering, Ohio, United States
🇺🇸Site US10039, Phoenix, Arizona, United States
🇺🇸Site US10051, Boston, Massachusetts, United States
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02236013
- Locations
- 🇺🇸
Site US10003, Los Angeles, California, United States
🇺🇸Site US10013, New Haven, Connecticut, United States
🇺🇸Site US10004, Chicago, Illinois, United States
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 888
- Registration Number
- NCT02216214
- Locations
- 🇺🇸
Site US00102, Norman, Oklahoma, United States
🇺🇸Site US00122, Greensboro, North Carolina, United States
🇺🇸Site US00112, Los Angeles, California, United States